DE19715504C2 - PMMA-Membranen mit Polyethylenglykol-gekoppelten Wirksubstanzen - Google Patents
PMMA-Membranen mit Polyethylenglykol-gekoppelten WirksubstanzenInfo
- Publication number
- DE19715504C2 DE19715504C2 DE19715504A DE19715504A DE19715504C2 DE 19715504 C2 DE19715504 C2 DE 19715504C2 DE 19715504 A DE19715504 A DE 19715504A DE 19715504 A DE19715504 A DE 19715504A DE 19715504 C2 DE19715504 C2 DE 19715504C2
- Authority
- DE
- Germany
- Prior art keywords
- peg
- membrane
- hirudin
- pmma
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920003229 poly(methyl methacrylate) Polymers 0.000 title claims abstract description 74
- 239000004926 polymethyl methacrylate Substances 0.000 title claims abstract description 74
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 67
- 239000012528 membrane Substances 0.000 title claims abstract description 64
- 239000013543 active substance Substances 0.000 title claims abstract description 23
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims description 48
- 239000008280 blood Substances 0.000 claims description 48
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical group C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 31
- 229940006607 hirudin Drugs 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 25
- 108010007267 Hirudins Proteins 0.000 claims description 23
- 102000007625 Hirudins Human genes 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 239000003146 anticoagulant agent Substances 0.000 claims description 7
- 229940127219 anticoagulant drug Drugs 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 4
- 239000000439 tumor marker Substances 0.000 claims 2
- 239000000463 material Substances 0.000 abstract description 7
- 229920001577 copolymer Polymers 0.000 abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 108010039231 polyethyleneglycol-hirudin Proteins 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- 239000000729 antidote Substances 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 108010046334 Urease Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102100033806 Alpha-protein kinase 3 Human genes 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229920002239 polyacrylonitrile Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002615 hemofiltration Methods 0.000 description 3
- 229940063557 methacrylate Drugs 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 108010080798 N(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide Proteins 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008275 binding mechanism Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- DZSVFMVMIXOYQZ-QRPNPIFTSA-N N1CCCCC1.C(N)(=N)C1=CC=C(C[C@H](N)C(=O)O)C=C1 Chemical compound N1CCCCC1.C(N)(=N)C1=CC=C(C[C@H](N)C(=O)O)C=C1 DZSVFMVMIXOYQZ-QRPNPIFTSA-N 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000158147 Sator Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 238000008083 Urea Assay Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108010085662 ecarin Proteins 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- OKXGHXHZNCJMSV-UHFFFAOYSA-N nitro phenyl carbonate Chemical compound [O-][N+](=O)OC(=O)OC1=CC=CC=C1 OKXGHXHZNCJMSV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- SZHIIIPPJJXYRY-UHFFFAOYSA-M sodium;2-methylprop-2-ene-1-sulfonate Chemical compound [Na+].CC(=C)CS([O-])(=O)=O SZHIIIPPJJXYRY-UHFFFAOYSA-M 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0093—Chemical modification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/14—Dynamic membranes
- B01D69/141—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes
- B01D69/1411—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes containing dispersed material in a continuous matrix
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/40—Polymers of unsaturated acids or derivatives thereof, e.g. salts, amides, imides, nitriles, anhydrides, esters
- B01D71/401—Polymers based on the polymerisation of acrylic acid, e.g. polyacrylate
- B01D71/4011—Polymethylmethacrylate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
- C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Manufacturing & Machinery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19715504A DE19715504C2 (de) | 1997-04-14 | 1997-04-14 | PMMA-Membranen mit Polyethylenglykol-gekoppelten Wirksubstanzen |
| AU75254/98A AU7525498A (en) | 1997-04-14 | 1998-04-14 | Interactive system for substance presentation and elimination |
| AT98922710T ATE380202T1 (de) | 1997-04-14 | 1998-04-14 | Interaktionssystem zur präsentation und entfernung von substanzen |
| EP98922710A EP0975680B1 (de) | 1997-04-14 | 1998-04-14 | Interaktionssystem zur präsentation und entfernung von substanzen |
| DE59814134T DE59814134D1 (de) | 1997-04-14 | 1998-04-14 | Interaktionssystem zur präsentation und entfernung von substanzen |
| EP07122292A EP1921094A3 (de) | 1997-04-14 | 1998-04-14 | Interaktionssystem zur Präsentation und Entfernung von Substanzen |
| CA2287469A CA2287469C (en) | 1997-04-14 | 1998-04-14 | Interactive system for presenting and eliminating substances |
| PCT/EP1998/002183 WO1998046648A1 (de) | 1997-04-14 | 1998-04-14 | Interaktionssystem zur präsentation und entfernung von substanzen |
| JP54349698A JP4495258B2 (ja) | 1997-04-14 | 1998-04-14 | 物質の供給および除去のための相互作用システム |
| ES98922710T ES2297886T3 (es) | 1997-04-14 | 1998-04-14 | Sistema de interaccion para la presentacion y retirada de sustancias. |
| US09/417,534 US6929955B2 (en) | 1997-04-14 | 1999-10-14 | Interactive system for presenting and eliminating substances |
| US11/170,666 US7494824B2 (en) | 1997-04-14 | 2005-06-29 | Interactive system for presenting and eliminating substances |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19715504A DE19715504C2 (de) | 1997-04-14 | 1997-04-14 | PMMA-Membranen mit Polyethylenglykol-gekoppelten Wirksubstanzen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE19715504A1 DE19715504A1 (de) | 1998-10-15 |
| DE19715504C2 true DE19715504C2 (de) | 2000-10-26 |
Family
ID=7826448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19715504A Expired - Fee Related DE19715504C2 (de) | 1997-04-14 | 1997-04-14 | PMMA-Membranen mit Polyethylenglykol-gekoppelten Wirksubstanzen |
| DE59814134T Expired - Lifetime DE59814134D1 (de) | 1997-04-14 | 1998-04-14 | Interaktionssystem zur präsentation und entfernung von substanzen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59814134T Expired - Lifetime DE59814134D1 (de) | 1997-04-14 | 1998-04-14 | Interaktionssystem zur präsentation und entfernung von substanzen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6929955B2 (enExample) |
| EP (2) | EP0975680B1 (enExample) |
| JP (1) | JP4495258B2 (enExample) |
| AT (1) | ATE380202T1 (enExample) |
| AU (1) | AU7525498A (enExample) |
| CA (1) | CA2287469C (enExample) |
| DE (2) | DE19715504C2 (enExample) |
| ES (1) | ES2297886T3 (enExample) |
| WO (1) | WO1998046648A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19845286A1 (de) * | 1998-10-01 | 2000-04-27 | Udo Dunzendorfer | Beschichtete Trägermaterialien für Blut-, Plasma- oder Gewebewäsche und mit diesen Trägermaterialien ausgerüstete Säulen |
| DE19909584A1 (de) * | 1999-03-04 | 2000-09-14 | Haemosys Gmbh | Trennverfahren |
| DE19915862A1 (de) * | 1999-04-08 | 2000-10-12 | Max Planck Gesellschaft | Verwendung von molekulargewichtserweitertem Hirudin als Antikoagulans bei der extrakorporalen Nierenersatztherapie |
| DE19918569A1 (de) * | 1999-04-23 | 2000-12-07 | Haemosys Gmbh | Verfahren zur Diagnose von Krankheiten, pathologischen Zuständen und pathophysiologischen sowie physiologischen Messgrößen |
| DE19955341A1 (de) * | 1999-11-17 | 2001-08-02 | Haemosys Gmbh | Blutkompatible Polymeroberflächen |
| AR027686A1 (es) * | 2000-03-20 | 2003-04-09 | Knoll Ag | Uso de sustancias inhibidoras de la coagulacion en el tratamiento extracorporeo de la sangre |
| KR100345323B1 (ko) * | 2000-04-24 | 2002-07-24 | 학교법인 포항공과대학교 | 나노 자성체 입자들을 포함하는 복합체 |
| DE10162521A1 (de) * | 2001-12-19 | 2003-07-17 | Goetz Nowak | Verwendung von molekulargewichtserweiterten Substanzen in der Tumortherapie |
| EP1443058A1 (en) | 2003-01-29 | 2004-08-04 | Firmenich Sa | Polymeric particles and fragrance delivery systems |
| DE10330900B4 (de) † | 2003-07-01 | 2006-09-14 | Leibniz-Institut Für Polymerforschung Dresden E.V. | Biomaterial mit einem modularen Beschichtungssystem zur Anwendung in Medizinprodukten mit direktem Blutkontakt |
| EG23584A (en) * | 2003-11-11 | 2006-09-11 | Ali Mokhtar Al-Hossary Amr | Elimination of myoglobin from blood using an i v filter |
| US9561309B2 (en) * | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
| DE102005001162A1 (de) * | 2005-01-10 | 2006-07-20 | Haemosys Gmbh | Adsorptionssystem zur Entfernung von Viren und viralen Bestandteilen aus Flüssigkeiten, insbesondere aus Blut und Blutplasma |
| AU2006312953B2 (en) * | 2005-11-14 | 2012-03-08 | Valorisation-Recherche, Limited Partnership | Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease |
| DE102007033787A1 (de) | 2007-07-09 | 2009-01-15 | Aesculap Ag | Gefäßprothese mit reduzierter Thrombogenität |
| DE102008000220A1 (de) * | 2008-02-01 | 2009-08-13 | ASCALON Gesellschaft für Innovation in der Medizintechnik m.b.H. | Hohlfaser-Separationsmembranen und Verfahren zu ihrer Herstellung |
| ES2620421T3 (es) | 2009-10-30 | 2017-06-28 | Senova Gesellschaft für Biowissenschaft und Technik mbH | Peptidasas acopladas a polímero |
| EP2620162A1 (de) | 2012-01-27 | 2013-07-31 | Life Science Inkubator | Enzym-Polymer-Konjugat zur Endotoxin-Detoxifikation |
| EP2892560B1 (en) * | 2012-09-06 | 2019-07-03 | Adelaide Research&Innovation Pty Ltd | Methods and products for preventing and/or treating metastatic cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1603393A (enExample) * | 1967-12-27 | 1971-04-13 | ||
| JPS4867382A (enExample) * | 1971-12-06 | 1973-09-14 | ||
| GB1484564A (en) * | 1974-07-24 | 1977-09-01 | Koch Light Labor Ltd | Stable support material for enzyme insolubilisation |
| FR2321520A1 (fr) * | 1975-08-22 | 1977-03-18 | Rhone Poulenc Ind | Latex de polymeres possedant des groupes-cn |
| DE2552510C3 (de) | 1975-11-22 | 1981-02-19 | Behringwerke Ag, 3550 Marburg | Biologisch aktive Verbindungen und Verfahren zu ihrer Herstellung |
| DE2712344C2 (de) * | 1977-03-21 | 1982-09-23 | Hans Dr. 4803 Steinhagen Bünemann | Löslicher Komplexbildner für die affinitätsspezifische Trennung von Nukleinsäuren |
| JPS57170263A (en) * | 1981-04-14 | 1982-10-20 | Kuraray Co | Absorber for blood protein |
| US4575539A (en) * | 1985-06-03 | 1986-03-11 | E. R. Squibb & Sons, Inc. | Drug delivery systems including novel interpenetrating polymer networks and method |
| JPH01310668A (ja) | 1988-06-09 | 1989-12-14 | Nikkiso Co Ltd | 中空糸型血液浄化装置 |
| CA1335142C (en) | 1989-07-18 | 1995-04-04 | Leon Edward St-Pierre | Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol |
| CA2040996A1 (en) * | 1990-05-02 | 1991-11-03 | Robert L. Albright | Composition and method for controlling cholesterol |
| US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| SE467309B (sv) * | 1990-10-22 | 1992-06-29 | Berol Nobel Ab | Hydrofiliserad fast yta, foerfarande foer dess framstaellning samt medel daerfoer |
| IL99862A (en) * | 1990-10-26 | 1995-06-29 | Genta Inc | Non-aromatic polymeric reactants for solid phase synthesis of oligomers |
| JPH06256394A (ja) * | 1991-08-13 | 1994-09-13 | Kirin Amgen Delaware Inc | 修飾インターロイキン６ |
| DE4203965A1 (de) | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
| US5578442A (en) * | 1992-03-23 | 1996-11-26 | Vivorx, Inc. | Graft copolymers of polycationic species and water-soluble polymers, and use therefor |
| DE4322884A1 (de) | 1992-10-09 | 1994-04-14 | Bayer Ag | Biologisch aktive Polymere |
| US5414075A (en) * | 1992-11-06 | 1995-05-09 | Bsi Corporation | Restrained multifunctional reagent for surface modification |
| DK0746582T3 (da) * | 1993-04-27 | 2000-08-21 | Cytotherapeutics Inc | Membran dannet af en acrylonitril-baseret polymer |
| FR2724461B1 (fr) | 1994-09-09 | 1996-12-20 | Prolabo Sa | Microsphere de latex biotinylee, procede de preparation d'une telle microsphere et utilisation en tant qu'agent de detection biologique |
| US5665428A (en) * | 1995-10-25 | 1997-09-09 | Macromed, Inc. | Preparation of peptide containing biodegradable microspheres by melt process |
| US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
| DE19625642A1 (de) | 1996-06-26 | 1998-01-08 | Max Planck Gesellschaft | Verfahren zur Herstellung einer Antidotausgangssubstanz für natürliche und synthetische Thrombininhibitoren |
-
1997
- 1997-04-14 DE DE19715504A patent/DE19715504C2/de not_active Expired - Fee Related
-
1998
- 1998-04-14 ES ES98922710T patent/ES2297886T3/es not_active Expired - Lifetime
- 1998-04-14 DE DE59814134T patent/DE59814134D1/de not_active Expired - Lifetime
- 1998-04-14 WO PCT/EP1998/002183 patent/WO1998046648A1/de not_active Ceased
- 1998-04-14 EP EP98922710A patent/EP0975680B1/de not_active Expired - Lifetime
- 1998-04-14 AT AT98922710T patent/ATE380202T1/de active
- 1998-04-14 AU AU75254/98A patent/AU7525498A/en not_active Abandoned
- 1998-04-14 CA CA2287469A patent/CA2287469C/en not_active Expired - Fee Related
- 1998-04-14 JP JP54349698A patent/JP4495258B2/ja not_active Expired - Fee Related
- 1998-04-14 EP EP07122292A patent/EP1921094A3/de not_active Withdrawn
-
1999
- 1999-10-14 US US09/417,534 patent/US6929955B2/en not_active Expired - Fee Related
-
2005
- 2005-06-29 US US11/170,666 patent/US7494824B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998046648A1 (de) | 1998-10-22 |
| US6929955B2 (en) | 2005-08-16 |
| CA2287469C (en) | 2010-02-09 |
| JP4495258B2 (ja) | 2010-06-30 |
| EP0975680A1 (de) | 2000-02-02 |
| JP2001527539A (ja) | 2001-12-25 |
| DE19715504A1 (de) | 1998-10-15 |
| DE59814134D1 (de) | 2008-01-17 |
| EP1921094A3 (de) | 2009-06-24 |
| EP1921094A2 (de) | 2008-05-14 |
| CA2287469A1 (en) | 1998-10-22 |
| ATE380202T1 (de) | 2007-12-15 |
| ES2297886T3 (es) | 2008-05-01 |
| US7494824B2 (en) | 2009-02-24 |
| AU7525498A (en) | 1998-11-11 |
| EP0975680B1 (de) | 2007-12-05 |
| US20050239131A1 (en) | 2005-10-27 |
| US20020028201A1 (en) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19715504C2 (de) | PMMA-Membranen mit Polyethylenglykol-gekoppelten Wirksubstanzen | |
| Chenoweth et al. | Anaphylatoxin formation during hemodialysis: Comparison of new and re-used dialyzers | |
| DE69433356T2 (de) | An der oberfläche modifizierte, biocompatible membranen | |
| Makita et al. | Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure | |
| DE60111688T2 (de) | Hämostatische lösliche zellulosefasern enthaltend ein koagulierendes protein zur behandlung von wunden und verfahren zu deren herstellung | |
| DE69603255T2 (de) | Verfahren zur modifizierung von oberflächen | |
| EP1852136A1 (en) | Use of a dialysis membrane for preparing a haemodialysis unit for reducing blood free light chain concentration | |
| Diamond et al. | Nonanticoagulant protective effect of heparin in chronic aminonucleoside nephrosis | |
| JP4234345B2 (ja) | 非凝塊形成性の半透膜及びその製法 | |
| EP0742022A4 (fr) | Hyrogel biocompatible | |
| DD283933A5 (de) | Hirudin-beschichtete biocompatible substanz | |
| DE60025698T2 (de) | Neue dialysemethode | |
| DE69624914T2 (de) | Vorrichtung und verfahren für die biospezifische entfernung von heparin | |
| DE112005001901T5 (de) | Einfangen und entfernen von Biomolekülen aus Körperflüssigkeiten unter Verwendung von partiellen molekularen Abdrücken | |
| DE2812174A1 (de) | Die blutgerinnung nicht foerdernde, biologisch vertraegliche gegenstaende | |
| DE2725608A1 (de) | Verfahren und vorrichtung zum kontinuierlichen entfernen von blutsubstanzen in einem extrakorporalen kreislauf | |
| DE69734511T2 (de) | Antigene modulation von zellen | |
| EP3102224A1 (en) | Methods and apparatus for kidney dialysis | |
| Kaenhy et al. | Relationship between dialyzer reuse and the presence of anti-N-like antibodies in chronic hemodialysis patients | |
| DE19981169B4 (de) | Kovalent an Gallensäuren oder Sterine gebundenes Heparin, dessen Verwendung und diese enthaltende pharmazeutische Zusammensetzung | |
| Inagaki et al. | Adsorption of nafamostat mesilate by hemodialysis membranes | |
| Sauer et al. | Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vitro and in vivo | |
| DE2732437B2 (de) | Wasserunlösliches Haptoglobinpräparat und Verfahren zu seiner Herstellung | |
| DE19955341A1 (de) | Blutkompatible Polymeroberflächen | |
| DE4428056A1 (de) | Verwendung von Mikropartikelpräparationen zur Eliminierung gelöster, nicht nierengängiger Substanzen aus dem Blut |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Effective date: 20131101 |